Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease
Official title: Impact of Drug-Coated Balloon Procedural Factors on Angiographic and Clinical Outcomes of Percutaneous Coronary Intervention for De Novo Lesions: A Multicenter, Prospective, Observational Registry
Run by Nanjing First Hospital, Nanjing Medical University · NCT07764094 · Data updated 2026-11-12
This registry tests whether delivery time and inflation duration of drug-coated balloons affect outcomes in adults undergoing PCI for new coronary lesions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Nanjing First Hospital, Nanjing Medical University Academic / other |
| Locations | 7 sites (Chuzhou, Anhui and 6 other locations) |
| Status | Recruiting |
| Started | September 1, 2026 |
| Main results expected | December 31, 2027 |
| Study ends | June 30, 2028 |
| Registry record updated | August 28, 2026 |
| Trial ID | NCT07764094 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 and older with stable CAD or unstable angina undergoing PCI for de novo lesions suitable for a DCB strategy.
✕Probably not a fit
Patients with recent MI, severe comorbidity, or contraindications to DCB components or dual antiplatelet therapy may not derive benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry analyzes how specific drug-coated balloon procedural factors, such as Y-to-B delivery time and inflation duration, influence both angiographic results and clinical outcomes in patients with de novo coronary lesions undergoing PCI. The study collects data on procedural details and subsequent outcomes to identify potential optimization strategies for the DCB treatment process. Based on the findings, new techniques and pretreatment approaches may be proposed to improve effectiveness and safety of DCB use. The design focuses on real-world practice across several hospitals in Anhui and Jiangsu, with adults meeting defined eligibility criteria. Outcome assessment will emphasize both short-term and longer-term clinical and imaging endpoints.
Why it matters
Potential benefit: If successful, the study could guide clinicians in optimizing DCB procedures to improve vessel healing and reduce adverse events.
How similar studies have gone: Prior work suggests procedural variables can influence DCB outcomes, though this registry may provide more precise guidance for optimized techniques.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years 2. Stable coronary artery disease or unstable angina 3. De novo coronary lesion (reference vessel diameter 2.25-4.0 mm; lesion length ≤40 mm) 4. Planned DCB strategy for PCI 5. Written informed consent Exclusion Criteria: 1. Acute myocardial infarction within 72 hours 2. Severe heart failure (NYHA class IV) 3. Severe hepatic or renal insufficiency 4. Allergy to drug-coated balloon components or antiplatelet agents, or intolerance to dual antiplatelet therapy 5. Life expectancy \<12 months 6. Pregnancy or breastfeeding 7. Concurrent participation in another clinical trial 8. In-stent restenosis 9. Unsuccessful recanalization of main vessel or side branch chronic total occlusion 10. Hemodynamic instability
Where it's running
-
Chuzhou First People's Hospital
Chuzhou, Anhui, China Recruiting -
Tongling People's Hospital
Tongling, Anhui, China Recruiting -
Huai'an Second People's Hospital
Huai'an, Jiangsu, China Recruiting -
Lianyungang First People's Hospital
Lianyungang, Jiangsu, China Recruiting -
Nanjing First Hospital
Nanjing, Jiangsu, China Recruiting -
Xuzhou Second People's Hospital
Xuzhou, Jiangsu, China Recruiting
Show 1 more location
-
Yixing People's Hospital
Yixing, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Fei Ye, MD
- Email: doctor_ye@126.com
- Phone: 18951670287
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SiroMax sirolimus-coated balloon for small coronary vessels with or without prior stents
A first-in-human test to see if the SiroMax drug-coated balloon can safely open narrow coronary arteries in adults with or without prior stents.
-
Bypass surgery versus stents for people with weak heart pumping and blockages in multiple coronary arteries
This trial tests whether bypass surgery (CABG) or stents (PCI) lead to better survival, fewer major heart problems, and improved quality of life for adults with reduced left ventricular function (LVEF ≤40%) and multivessel coronary disease.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.